Do you treat muscle-invasive urothelial bladder cancer with plasmacytoid features any differently in terms of the recommendation for neoadjuvant cisplatin-based chemotherapy?   

Plasmacytoid variant carcinoma is a rare aggressive variant that tends to be chemosensitive but recurs frequently and is characterized by CDH1 loss of function genomic alterations and peritoneal metastasis. In predominant plasmacytoid urothelial carcinoma, the role of neoadjuvant chemotherapy (NAC) ...